One possibility is that soluble P‐tau217 plays a role in the spread of neocortical tangles, which could motivate trials with treatments targeting soluble phosphorylated tau, to break the link between Aβ and tau aggregation in AD. The gene discussed is MAPT; the disease is Alzheimer disease.